|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 409 12th Street, SW |
Address2 |
|
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
|
5. Senate ID# 400578740-12
|
||||||||
|
6. House ID# 412490000
|
||||||||
| TYPE OF REPORT | 8. Year | 2025 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kira Peterson |
Date | 10/16/2025 3:39:14 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
WIC (general); SNAP (general)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lillie |
Heyman |
|
|
|
Sarah |
Bogdan |
|
|
|
Rebecca |
Lauer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Womens health research (general); Centers for Disease Control and Prevention (CDC); National Institutes of Health (NIH); NIH Office of Research on Womens Health; Health Resources and Services Administration (HRSA); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Alliance for Innovation on Maternal Health (HRSA); Safe Motherhood and Infant Health Program (CDC); National Center for Chronic Disease Prevention and Health Promotion (CDC); Substance Abuse and Mental Health Services Administration (SAMHSA); Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC); inclusion of pregnant and lactating people in clinical trials (general); Congressionally Directed Medical Research Program; Title X family planning program; Title V Maternal and Child Health Block Grant; Title VII Health Professions and Title VIII Nursing Workforce Development programs IHS loan repayment and scholarship programs; IHS staff quarters; IHS medical and diagnostic equipment; Office on Smoking and Health (CDC); Pregnancy Risk Assessment Monitoring System (CDC); NIH restructuring (general); SET-NET (CDC); Teaching Health Center Graduate Medical Education Program (THCGME); HHS reorganization (general); FY2026 Labor, Health and Human Services, and Education, and Related Agencies appropriations bill; FY 2026 Defense Appropriations Bill
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rachel |
Tetlow |
|
|
|
Sarah |
Bogdan |
|
|
|
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code EDU
16. Specific lobbying issues
Federal student loan programs (general); Grad PLUS loans (general); student loan interest deferral (general); P.L. 119-21, One Big, Beautiful Bill Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
|
Sarah |
Bogdan |
|
|
|
Rachel |
Tetlow |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Abortion access (general); Access to mifepristone (general); Contraception (general); Maternal mortality and morbidity (general); Advancing Safe Medications for Moms and Babies Act; E21 Inclusion of Pregnant and Breastfeeding Women in Clinical Trials Draft Guidance (FDA-2025-D-1797); ;Obstetric and gynecologic care in rural and underserved areas (general); impact of closures of labor and delivery units in rural hospitals on patient access to care and maternal morbidity and mortality; abortion training in obstetrics and gynecology residency programs (general); Teaching Health Center Graduate Medication Education program (general); P.L. 119-21, One Big, Beautiful Bill Act; H.R. 1909/S. 2621, Preventing Maternal Deaths Reauthorization Act of 2025; Telemedicine (general); S. 2858/H.R. 5469, SHINE for Autumn Act; S. 380/H.R. 1254, Rural Obstetrics Readiness Act; S. 2439/H.R4731, Resident Physician Shortage Reduction Act; S. 1834/H.R. 3762, Supporting Healthy Moms and Babies Act; S. 942/H.R. 2028, REDI Act; Implementation of P.L. 117-328, Pregnant Workers Fairness Act; National Health Service Corps (general); Public Service Loan Forgiveness program (general); maternal mortality review committees (general); HIPAA (general); reductions in force at HHS (general); caps on indirect research costs at NIH (general); removal of CDC online guidance (general); Patient-physician relationship (general); Obstetrician-gynecologist workforce (general); Substance use disorder during pregnancy (general); Maternal mental health (general); Insurance coverage for infertility (general); Protections for in vitro fertilization (general); Vaccination (general); Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) recommendations (general); NIH/NICHD womens health research (general); access to fertility services and treatments (general); funding for providers of reproductive health care (general); IUD insertion (general); health IT (general); prepregnancy health (general); Affordable Care Act (general); Advisory Committee on Immunization Practices (ACIP); COVID vaccine during pregnancy (general); H.R. 4977/S. 141, Connected MOM Act; S. 2408/H.R. 4648, Access to Fertility Treatment and Care Act; H.R. 4611/S.2377, EACH Act; S. 1599, Midwives for MOMS Act; S. 1562/H.R. 1197, PREEMIE Reauthorization Act; S. 1380/H.R.4681, SPARC Act; S.Res. 401/H.Res. 739, National Stillbirth Prevention and Awareness Day Resolution; H.R. 4331, Access to Claims Data Act; H.R. 4417, Mobile Cancer Screening Act; S.____, Maternal Health Pandemic Response Act; H.R.____, HIV Medication Access Act; United States Preventive Services Taskforce (general); remote blood pressure monitoring (general); pelvic floor therapy (general); Affordable Care Act contraceptive mandate (general); pain management during gynecologic procedures (general); hormone therapy for menopause symptoms (general); acetaminophen use during pregnancy (general); SSRI use during pregnancy (general); federal HIV guidelines (general); HPV testing (general); ; premenstrual dysphoric disorder (general); Pregnancy Risk Assessment Monitoring System (PRAMS); S.2296, National Defense Authorization Act for Fiscal Year 2026; H.R.3838, Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rachel |
Tetlow |
|
|
|
Sarah |
Bogdan |
|
|
|
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 879, Medicare Patient Access and Practice Stabilization Act of 2025; H.R. 5448, Protecting Free Vaccines Act; Physician payment under Medicare (general); Graduate medical education (general); Prior authorization in Medicare (general); Medicaid (general); Medicaid work requirements (general); CMS billing and coding procedures (general); preserving postpartum Medicaid extension (general); P.L. 119-21, One Big, Beautiful Bill Act; telehealth (general)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rachel |
Tetlow |
|
|
|
Sarah |
Bogdan |
|
|
|
Rebecca |
Lauer |
|
|
|
Lillie |
Heyman |
|
|
|
Lisa |
Satterfield |
|
|
|
Taylor |
Platt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
Physicians with H-1B visas (general); J-1 visas Duration of Status (general)
17. House(s) of Congress and Federal agencies Check if None
Homeland Security - Dept of (DHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Lillie |
Heyman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
H.R. 4855/S. 2534, Veteran Families Health Services Act; Abortion policy at the Department of Veterans Affairs (general); Menopause care at the Department of Veterans Affairs (general)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rebecca |
Lauer |
|
|
|
Sarah |
Bogdan |
|
|
|
Lillie |
Heyman |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |